Skip to Main Content


Skip Nav Destination

Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial

Cancer Res (2018) 78 (13_Supplement): CT179.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Anne Catherine Bretz
  • Ulrike Parnitzke
  • Kerstin Kronthaler
  • Tobias Dreker
  • René Bartz
  • Frank Hermann
  • Astrid Ammendola
  • Tanja Wulff
  • Svetlana Hamm
Journal for ImmunoTherapy of Cancer (2019) 7 (1)
Close Modal

or Create an Account

Close Modal
Close Modal